Nancy L Ascher, MD
General Surgery · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Offices
- 2
- Since medical school
- 52 years
- University of Michigan Medical School, 1974
Offices
2 locations · UCSF Dept of Surgery · UCSF Medical Group Business Services
Looking this up.
Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Ascher’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence G63147 · Current
Licensed to practise in California · since 1988 · expires 2028-03-31 · University of Michigan Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$13,696
Medicare paid this office $13,696 for 42 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 22 | $2,467 | $80 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 13 | $2,218 | $106 |
Who their Medicare patients are
42 Original Medicare patients in 2024. Average age 66 · Women 43% · Also on Medicaid 48% · Health risk score 4.52. Sicker patients than 9 in 10 peers; the typical general surgery clinician is at 1.69.
Conditions among them: High blood pressure 75% · Chronic kidney disease 74% · Diabetes 71% · Coronary heart disease 43% · Heart failure 29% · Atrial fibrillation 26%.
The office billed $157,866, Medicare allowed $17,463 and paid $13,696; for 76 services of 13 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 42 | 76 | 66 | 4.52 | $157,866 | $13,696 |
| 2023 | 57 | 116 | 65 | 4.43 | $599,290 | $57,511 |
| 2022 | 60 | 110 | 64 | 4.28 | $464,444 | $45,906 |
| 2021 | 68 | 129 | 64 | 3.98 | $583,097 | $61,764 |
| 2020 | 55 | 122 | 62 | 4.97 | $589,415 | $60,082 |
| 2019 | 81 | 132 | 64 | 5.26 | $382,329 | $39,964 |
| 2018 | 85 | 142 | 64 | 5.61 | $731,153 | $72,560 |
| 2017 | 78 | 142 | 59 | 5.65 | $590,473 | $57,844 |
| 2016 | 64 | 87 | 59 | 4.91 | $442,083 | $41,072 |
| 2015 | 91 | 148 | 60 | 5.46 | $619,497 | $61,387 |
| 2014 | 118 | 211 | 60 | 5.34 | $845,647 | $80,018 |
| 2013 | 119 | 253 | 58 | 5.76 | $888,923 | $90,027 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 3 services
| Return visit (30+ min) | 24 | $2,974 | $87 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $2,126 | $106 |
| Short return visit (20+ min) | 11 | $591 | $54 |
2022: 2 services
| Return visit (30+ min) | 17 | $1,549 | $77 |
| Short return visit | 19 | $865 | $31 |
2021: 3 services
| Return visit (30+ min) | 19 | $2,410 | $83 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $2,338 | $94 |
| Long return visit (40+ min) | 11 | $2,147 | $134 |
2020: 1 service
| Return visit (30+ min) | 24 | $3,121 | $73 |
2019: 3 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 27 | $2,806 | $65 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 13 | $2,144 | $93 |
| Return visit (30+ min) | 24 | $1,699 | $65 |
2018: 3 services
| Transplantation of donor kidney | 14 | $29,484 | $2,106 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 32 | $3,299 | $65 |
| Return visit (30+ min) | 21 | $1,467 | $64 |
2017: 2 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 32 | $3,748 | $65 |
| Return visit (30+ min) | 16 | $939 | $55 |
2016: 1 service
| Return visit (30+ min) | 22 | $1,571 | $68 |
2015: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 32 | $2,673 | $65 |
| Return visit (30+ min) | 15 | $977 | $65 |
| Short return visit (20+ min) | 14 | $633 | $42 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 13 | $455 | $35 |
2014: 6 services
| Transplantation of donor kidney | 12 | $25,470 | $2,123 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 39 | $3,761 | $63 |
| Return visit (30+ min) | 17 | $1,181 | $69 |
| New patient visit (45+ min) | 11 | $1,163 | $106 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 22 | $906 | $35 |
| Short return visit (20+ min) | 20 | $805 | $40 |
2013: 5 services
| Transplantation of donor kidney | 15 | $34,062 | $2,271 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 59 | $7,340 | $63 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 27 | $1,217 | $34 |
| Preparation of donor kidney for transplantation | 11 | $865 | $79 |
| Short return visit (20+ min) | 15 | $612 | $41 |
Drugs they prescribed that Part D paid
$26,511
Pharmacies billed $26,511 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 219) in 2024. At or below the middle of the specialty; the typical general surgery clinician is at 34%. Surgeons prescribe little besides pain medicine after an operation, so their opioid share runs high.
189 generic and fewer than 11 brand-name prescriptions · $26,511 in drug cost · 19 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Tenofovir Disoproxil | 15 | $432 | $29 |
| Prednisone | 15 | $150 | $10 |
| Omeprazole | 21 | $143 | $7 |
| Pantoprazole | 11 | $137 | $12 |
| Sulfamethoxazole-Trimethoprim | 17 | $100 | $6 |
See all 6 drugs
| Tenofovir Disoproxil | 15 | $432 | $29 |
| Prednisone | 15 | $150 | $10 |
| Omeprazole | 21 | $143 | $7 |
| Pantoprazole | 11 | $137 | $12 |
| Sulfamethoxazole-Trimethoprim | 17 | $100 | $6 |
| Clopidogrel | 12 | $23 | $2 |
Year by year
| 2024 | 219 | 22 | 0% (0) | None | $26,511 |
| 2023 | 180 | 24 | 0% (0) | None | $24,376 |
| 2022 | 157 | 25 | None | None | $17,347 |
| 2021 | 270 | 35 | 0% (0) | 12% | $53,032 |
| 2020 | 158 | 32 | 0% (0) | None | $30,195 |
| 2019 | 182 | 36 | None | None | $26,418 |
| 2018 | 166 | 33 | None | None | $51,531 |
| 2017 | 284 | 37 | None | None | $52,975 |
| 2016 | 312 | 47 | None | 18% | $87,866 |
| 2015 | 290 | 46 | None | 20% | $91,688 |
| 2014 | 268 | 43 | None | None | $114,855 |
| 2013 | 224 | 46 | None | None | $122,681 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 5 drugs
| Valganciclovir | 15 | $2,900 | $193 |
| Pantoprazole | 18 | $329 | $18 |
| Omeprazole | 23 | $256 | $11 |
| Sulfamethoxazole-Trimethoprim | 24 | $163 | $7 |
| Prednisone | 15 | $152 | $10 |
2022: 6 drugs
| Valganciclovir | 14 | $3,226 | $230 |
| Mycophenolate Mofetil | 11 | $1,555 | $141 |
| Lamivudine Hbv | 11 | $1,282 | $117 |
| Sulfamethoxazole-Trimethoprim | 26 | $150 | $6 |
| Prednisone | 15 | $146 | $10 |
| Omeprazole | 16 | $101 | $6 |
2021: 8 drugs
| Valganciclovir | 19 | $19,912 | $1,048 |
| Entecavir | 13 | $7,647 | $588 |
| Mycophenolate Mofetil | 23 | $2,160 | $94 |
| Metoprolol | 17 | $358 | $21 |
| Pantoprazole | 16 | $187 | $12 |
| Omeprazole | 21 | $143 | $7 |
| Sulfamethoxazole-Trimethoprim | 18 | $106 | $6 |
| Prednisone | 17 | $105 | $6 |
2020: 4 drugs
| Valganciclovir | 18 | $16,476 | $915 |
| Prednisone | 23 | $130 | $6 |
| Sulfamethoxazole-Trimethoprim | 19 | $84 | $4 |
| Omeprazole | 13 | $54 | $4 |
2019: 5 drugs
| Valganciclovir | 18 | $12,779 | $710 |
| Terazosin | 11 | $123 | $11 |
| Omeprazole | 14 | $113 | $8 |
| Fluconazole | 12 | $77 | $6 |
| Sulfamethoxazole-Trimethoprim | 16 | $76 | $5 |
2018: 3 drugs
| Valganciclovir | 20 | $37,387 | $1,869 |
| Prednisone | 13 | $249 | $19 |
| Sulfamethoxazole-Trimethoprim | 21 | $190 | $9 |
2017: 7 drugs
| Mycophenolic Acid | 22 | $14,678 | $667 |
| Tacrolimus | 16 | $2,880 | $180 |
| Dapsone | 14 | $1,653 | $118 |
| Mycophenolate Mofetil | 13 | $1,242 | $96 |
| Omeprazole | 35 | $325 | $9 |
| Prednisone | 20 | $312 | $16 |
| Sulfamethoxazole-Trimethoprim | 28 | $274 | $10 |
2016: 7 drugs
| Valganciclovir | 20 | $53,358 | $2,668 |
| Humalog | 13 | $1,184 | $91 |
| Omeprazole | 21 | $418 | $20 |
| Prednisone | 33 | $360 | $11 |
| Sulfamethoxazole-Trimethoprim | 25 | $248 | $10 |
| Ciprofloxacin | 15 | $78 | $5 |
| Amlodipine Besylate | 15 | $42 | $3 |
2015: 6 drugs
| Valganciclovir | 12 | $41,627 | $3,469 |
| Omeprazole | 26 | $782 | $30 |
| Dapsone | 12 | $383 | $32 |
| Tamsulosin | 13 | $264 | $20 |
| Sulfamethoxazole-Trimethoprim | 40 | $229 | $6 |
| Carvedilol | 11 | $63 | $6 |
2014: 6 drugs
| Valcyte | 19 | $80,460 | $4,235 |
| Dapsone | 11 | $1,717 | $156 |
| Omeprazole | 33 | $743 | $23 |
| Prednisone | 23 | $405 | $18 |
| Sulfamethoxazole-Trimethoprim | 32 | $223 | $7 |
| Fluconazole | 14 | $181 | $13 |
2013: 7 drugs
| Valcyte | 16 | $44,616 | $2,789 |
| Truvada | 17 | $26,058 | $1,533 |
| Tacrolimus | 15 | $3,776 | $252 |
| Mycophenolate Mofetil | 13 | $1,330 | $102 |
| Omeprazole | 31 | $945 | $30 |
| Sulfamethoxazole-Trimethoprim | 24 | $284 | $12 |
| Prednisone | 12 | $127 | $11 |
Money from drug and device companies
$397 in 2019
A payment is not proof that care is biased.
| One Lambda | None | $397 | 1 payment
|
See the published payment
| One Lambda | Travel · 2019-01-22 | None | $397 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 75.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1396799516
- Licence
- CA G63147California G63147: Current · expires 2028-03-31
- Trained
- University of Michigan Medical School, 1974 · 52 years ago
- Group
- UCSF Dept of Surgery · UCSF Medical Group Business Services
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00G631470
- Taxonomy
- Surgery (208600000X); Federal specialty code 204F00000X (204F00000X); Surgical oncology (2086X0206X)
- Mailing address
- 1635 Divisadero Street, Suite 625, Box 1821, San Francisco, CA, 94143
- NPI first listed
- 2006-05-20
- NPI last updated
- 2008-07-23
This is when the NPI record was last certified, not a medical board exam.